Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung CancerBiagio Ricciuti, Mark M. Awad, Giuseppe Lamberti et al.|Journal of Clinical Oncology|2024Cited by 124
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerBiagio Ricciuti, Jia Luo, Federica Pecci et al.|Annals of Oncology|2022Cited by 100
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLCJoao V. Alessi, Mark M. Awad, Arielle Elkrief et al.|Journal of Thoracic Oncology|2023Cited by 91
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLCFederica Pecci, Xiuning Le|Clinical Cancer Research|2025Cited by 6